Lexeo Therapeutics Inc. Common Stock (LXEO)
Stock · NASDAQ · Health Care
$2.64as of 10/16/2026
Price chart
Active signals
High Beta34.6%
200 SMA Touch0.0%Resistance level
$4.69
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
LXEO Signal Track Record
How signals performed across all stocks →What LXEO's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 24 | -5.2% | 46% | September 29, 2026 |
| Bollinger Band Breakdown | 11 | -8.6% | 36% | September 23, 2026 |
| Bollinger Band Breakout | 8 | -15.8% | 38% | August 19, 2026 |
| Any 20-session window (baseline) | -3.5% | 43% |
Computed by MarketWall from daily closing prices since August 21, 2024. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About LXEO
Lexeo Therapeutics, Inc., a clinical stage genetic medicine company, focuses on hereditary and acquired diseases with high unmet need in the United States. Its product pipeline comprises LX2006, an AAVrh10-based gene therapy candidate, which is in phase 1/2 clinical trial to treat friedreich ataxia cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate, which is in phase 1/2 to deliver a functional plakophil…
- Sector
- Health Care
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Employees
- 63
- Website
- www.lexeotx.com/
Fundamentals
- 1-day range
- $2.61$2.83
- Market cap
- $357.27M
- P/E (trailing)
- —
- P/E (forward)
- -2.02
- EPS (trailing)
- $-1.16
- Dividend yield
- —
- Beta
- 1.67
- Avg. volume
- 1.25M
52-week range
$2.56$10.99
Next earnings: November 4, 2026 · EPS estimate $-0.32confirmed
Forecasts
10 analyst ratings
Buy 94%
Hold 6%
Sell 0%
1-year price forecast
High
$30
+1038.5%
Median
$20
+659.0%
Low
$9
+241.6%
Lexeo Therapeutics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- LXEOLexeo Therapeutics Inc. Common Stock$2.64▼ 4.35%Market cap $357.27MP/E —$2.56$10.99
- CMPXCompass Therapeutics Inc. Common Stock$0.86▼ 4.12%Market cap $358.37MP/E —$0.8294$6.88
- PALIPalisade Bio Inc. Common Stock$1.41▼ 8.44%Market cap $362.78MP/E —$1.32$2.86
- IPSCCentury Therapeutics Inc. Common Stock$1.37▼ 8.67%Market cap $342.67MP/E —$0.435$3.04
- FENCFennec Pharmaceuticals Inc. Common Stock$9.98▼ 3.57%Market cap $378.17MP/E —$5.65$13.25
- AGENAgenus Inc. Common Stock$6.04▼ 9.58%Market cap $335.19MP/E 3.19$2.71$10.31
- XFORX4 Pharmaceuticals Inc. Common Stock$2.59▼ 1.89%Market cap $393.31MP/E 3.24$2.43$4.83
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| LXEO Lexeo Therapeutics Inc. Common Stock | $357.27M | — | $2.64 | ▼ 4.35% | $2.56$10.99 |
| CMPX Compass Therapeutics Inc. Common Stock | $358.37M | — | $0.86 | ▼ 4.12% | $0.8294$6.88 |
| PALI Palisade Bio Inc. Common Stock | $362.78M | — | $1.41 | ▼ 8.44% | $1.32$2.86 |
| IPSC Century Therapeutics Inc. Common Stock | $342.67M | — | $1.37 | ▼ 8.67% | $0.435$3.04 |
| FENC Fennec Pharmaceuticals Inc. Common Stock | $378.17M | — | $9.98 | ▼ 3.57% | $5.65$13.25 |
| AGEN Agenus Inc. Common Stock | $335.19M | 3.19 | $6.04 | ▼ 9.58% | $2.71$10.31 |
| XFOR X4 Pharmaceuticals Inc. Common Stock | $393.31M | 3.24 | $2.59 | ▼ 1.89% | $2.43$4.83 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- Lexeo Therapeutics to Participate in the Chardan Healthcare ConferenceYahoo · 10/8/2026
- Lexeo Therapeutics Announces Oral Presentation of LX2006 at the International Congress of Parkinson’s Disease and Movement Disorders 2026 (MDS)Yahoo · 10/1/2026
- Apertura Gene Therapy to Provide Lexeo Therapeutics Access to TfR1 CapX™ for Program Designed to Treat Friedreich AtaxiaYahoo · 9/23/2026
- Lexeo Therapeutics to Participate in the Stifel 2026 Virtual Cardiometabolic ForumYahoo · 9/23/2026
- Lexeo Therapeutics, Inc. (LXEO) M&A Call TranscriptSeekingAlpha · 9/22/2026
- Lexeo Therapeutics, Inc. (LXEO) Mantle Therapeutics Inc. - M&A Call - SlideshowSeekingAlpha · 9/22/2026
- Lexeo Therapeutics Announces Deal To Acquire Mantle Therapeutics For $8.3M Upfront, Up To $13M In Milestones, Adding Friedreich Ataxia Programsbenzinga · 9/22/2026
- Lexeo Therapeutics Enters Into Agreement to Acquire Mantle Therapeutics and Announces Multiple New Strategic Collaborations to Expand Leadership in Friedreich AtaxiaYahoo · 9/22/2026
- Ericsson, Lexeo Therapeutics And Other Big Stocks Moving Lower In Tuesday’s Pre-Market SessionBenzinga · 9/22/2026
Insider Activity
Insider Actions →Acquired
371.9K
Disposed
66.3K
- Bhalla Narinder Pal · September 24, 2026 · Grant54.8K
- Tamayo Louis Edward · September 24, 2026 · Grant54.8K
- Otero Jose Manuel · September 24, 2026 · Grant54.8K
- Townsend Richard Nolan · September 24, 2026 · Grant145.5K
- Bhalla Narinder Pal · September 14, 2026 · Grant2.7K @ $3.58
- Otero Jose Manuel · September 14, 2026 · Grant2.1K @ $2.64
- Townsend Richard Nolan · September 14, 2026 · Grant2.3K @ $2.64
- Tamayo Louis Edward · August 18, 2026 · Sale4.1K @ $4.91
- Otero Jose Manuel · August 18, 2026 · Sale1.3K @ $4.96
- Townsend Richard Nolan · August 18, 2026 · Sale3.3K @ $4.95
- Tamayo Louis Edward · July 1, 2026 · Sale4.6K @ $4.49
- Otero Jose Manuel · July 1, 2026 · Sale4.7K @ $4.48
- Townsend Richard Nolan · July 1, 2026 · Sale25.9K @ $4.48
- Bhalla Narinder Pal · July 1, 2026 · Sale22.3K @ $4.42
- Bhalla Narinder Pal · June 29, 2026 · Grant55.0K
Institutional Ownership
March 31, 2026
- Total shares held
- 78.76M
- Total value held
- $451.75M
- Institutional holders
- 134
Top holders this quarter
- Unknown6.18M
- Unknown5.11M
- Unknown5.05M
- Unknown5.00M
- Unknown4.98M
- Unknown4.47M
- Unknown4.42M
- Unknown3.85M
- Unknown3.60M
- Unknown3.57M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 26, 2026
LXEO to Acquire Mantle Therapeutics, Expand Friedreich Ataxia Programs
Lexeo Therapeutics announced an agreement to acquire Mantle Therapeutics and enter new collaborations to expand its Friedreich Ataxia portfolio. The company also secured access to Apertura’s TfR1 CapX technology for its treatment programs. These strategic moves aim to strengthen Lexeo's position in the rare disease space, though the stock remains in a technical downtrend.
LXEO to Acquire Mantle Therapeutics, Expand Friedreich Ataxia Programs. Lexeo Therapeutics announced an agreement to acquire Mantle Therapeutics and enter new collaborations to expand its Friedreich Ataxia portfolio. The company also secured access to Apertura’s TfR1 CapX technology for its treatment programs. These strategic moves aim to strengthen Lexeo's position in the rare disease space, though the stock remains in a technical downtrend.